lewy-body-pathogenesis

Lewy Body Pathogenesis

Overview

Lewy Body Pathogenesis describes the molecular and cellular mechanisms underlying the formation, composition, and spread of Lewy bodies—the intraneuronal inclusions that serve as the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Understanding Lewy body formation, composition, and propagation is essential for developing disease-modifying therapies targeting the underlying proteinopathy.

Lewy bodies are composed primarily of aggregated alpha-synuclein (α-syn) protein and represent a convergence point for multiple pathogenic mechanisms including protein misfolding, impaired clearance, post-translational modifications, and prion-like propagation.

Historical Context

Frederick Lewy first described spherical inclusions in the substantia nigra in 1912, now known as Lewy bodies. For decades, their significance was debated, but they are now recognized as central to the pathogenesis of the synucleinopathies.

Key historical milestones:

• 1912: First description by Frederick Lewy
• 1997: α-Synuclein identified as main component by Spillantini et al.
• 1998: Ubiquitination demonstrated in Lewy bodies
• 2003: Braak staging hypothesis published
• 2012: First demonstration of template-driven propagation
• 2015: Discovery of distinct α-syn strains

Composition and Structure

Core Components

Lewy bodies contain a dense core surrounded by a halo of radiating filaments:

...

Lewy Body Pathogenesis

Overview

Lewy Body Pathogenesis describes the molecular and cellular mechanisms underlying the formation, composition, and spread of Lewy bodies—the intraneuronal inclusions that serve as the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Understanding Lewy body formation, composition, and propagation is essential for developing disease-modifying therapies targeting the underlying proteinopathy.

Lewy bodies are composed primarily of aggregated alpha-synuclein (α-syn) protein and represent a convergence point for multiple pathogenic mechanisms including protein misfolding, impaired clearance, post-translational modifications, and prion-like propagation.

Historical Context

Frederick Lewy first described spherical inclusions in the substantia nigra in 1912, now known as Lewy bodies. For decades, their significance was debated, but they are now recognized as central to the pathogenesis of the synucleinopathies.

Key historical milestones:

• 1912: First description by Frederick Lewy
• 1997: α-Synuclein identified as main component by Spillantini et al.
• 1998: Ubiquitination demonstrated in Lewy bodies
• 2003: Braak staging hypothesis published
• 2012: First demonstration of template-driven propagation
• 2015: Discovery of distinct α-syn strains

Composition and Structure

Core Components

Lewy bodies contain a dense core surrounded by a halo of radiating filaments:

| Component | Location | Function/Relevance |
|-----------|----------|-------------------|
| Alpha-synuclein | Core and halo | Principal component, misfolded |
| Ubiquitin | Halo | Protein degradation marker |
| p62 | Core | Selective autophagy receptor |
| Neurofilaments | Halo | Cytoskeletal proteins |
| Lysosomal proteins | Core | Autophagy-lysosomal pathway |
| Mitochondrial proteins | Variable | Mitochondrial dysfunction |
| CHCHD2 | Variable | Mitochondrial function |
| Alsin | Variable | ALS-related protein |

Morphological Types

Brainstem Lewy Bodies:

• Classic form with dense core and radiating halo
• 5-25 μm diameter
• Located in substantia nigra, locus coeruleus
• Associated with typical PD

Cortical Lewy Bodies:

• Less defined, diffuse appearance
• Primarily in neocortex and limbic system
• Associated with dementia (DLB, PDD)
• Less likely to have halo structure

Incertus (Locus Incertus) Lewy Bodies:

• Recently described variant
• Located in the incertus nucleus
• May have specific clinical correlations

Formation Mechanisms

1. Alpha-Synuclein Misfolding

The process of Lewy body formation begins with α-syn misfolding:

Key triggers:

• Genetic mutations (SNCA duplication, A53T, A30P, E46K)
• Oxidative stress
• Mitochondrial dysfunction
• Impaired autophagy
• Metal ion interactions (iron, copper)
• Membrane binding

2. Impaired Protein Clearance

Two major cellular clearance pathways are implicated:

Ubiquitin-Proteasome System (UPS):

• Reduced proteasome activity in PD brains
• Failure to clear misfolded proteins
• Ubiquitinated proteins accumulate
• Proteasome subunits show dysfunction

Autophagy-Lysosome Pathway:

• Reduced lysosomal function (GBA mutations increase risk)
• Impaired mitophagy (PINK1, Parkin mutations)
• Macroautophagy defects
• Chaperone-mediated autophagy impairment

3. Post-Translational Modifications

Alpha-synuclein undergoes multiple modifications that promote aggregation:

| Modification | Site | Effect |
|--------------|------|--------|
| Phosphorylation | Ser129 (>90% in LBs) | Enhanced aggregation |
| Phosphorylation | Ser87 | Reduced aggregation |
| Nitration | Tyr125, Tyr133, Tyr136 | Stabilizes oligomers |
| Oxidation | Met1, Met5, Met116 | Conformational change |
| Truncation | C-terminal cleavage | Promotes aggregation |
| SUMOylation | K96, K102 | May promote clearance |
| Ubiquitination | Multiple sites | Target for degradation |

The phosphorylation at Ser129 is particularly significant, with >90% of α-syn in Lewy bodies being phosphorylated at this site, making it a diagnostic biomarker and therapeutic target[@fujiwara2002].

Propagation Mechanisms

Prion-Like Spreading

Lewy body pathology spreads in a predictable pattern (Braak staging)[@braak2003]:

Stage 1: Olfactory bulb (early, sporadic PD)

Stage 2: Brainstem (locus coeruleus/substantia nigra)

Stage 3: Mesocortex (limbic system)

Stage 4: Neocortex (advanced disease)

Stage 5-6: Higher-order neocortical areas

This progression suggests trans-synaptic spread of pathological α-syn, though the exact mechanism remains under investigation.

Mechanisms of Spread

| Mechanism | Description | Evidence |
|-----------|-------------|----------|
| Synaptic transmission | Release and uptake at synapses | High in olfactory bulb |
| Tunneling nanotubes | Direct cell-to-cell transfer | In vitro demonstrations |
| Extracellular vesicles | Exosome-mediated spread | Detected in CSF |
| Free diffusion | Tissue interstitial space | Limited evidence |

Evidence for Prion-Like Properties

• Braak hypothesis of progressive spread demonstrated in numerous studies
• Experimental models show fibril uptake and intracellular templating
• Patient-derived α-syn fibrils are infectious in mouse models
• Fetal mesencephalic transplants develop Lewy pathology after 10+ years[@mcenaney2020]
• Different strains show distinct propagation patterns

Template-Directed Misfolding

The prion-like nature involves:

Seed formation: Pathological α-syn acts as template

Template propagation: Normal α-syn adopts pathological conformation

Strain maintenance: Distinct conformations are preserved

Strain adaptation: Different strains cause different diseases

α-Synuclein Strains

Different α-synuclein conformations ("strains") may determine disease phenotype[@peelaerts2015]:

• PD-associated strains: More propagative, less toxic
• DLB-associated strains: More cytotoxic, distinct aggregation
• MSA-associated strains: Distinct biochemical properties
• Strain-specific therapeutic targeting: Emerging concept

Strains differ in:

• Fibril structure (cryo-EM reveals distinct folds)
• Aggregation kinetics
• Cellular distribution
• Neurotoxicity profiles
• Response to small molecule inhibitors

Regional Vulnerability

Most Affected Regions

• Substantia nigra pars compacta: Dopaminergic neuron loss
• Locus coeruleus: Noradrenergic neurons
• Nucleus basalis of Meynert: Cholinergic dysfunction
• Dorsal motor nucleus of vagus: Autonomic dysfunction
• Olfactory bulb: Anosmia, early pathology
• Amygdala: Limbic system involvement
• Cortex: Variable, especially in DLB

Vulnerability Factors

Multiple factors explain selective neuronal vulnerability:

Neuronal size: Large neurons more vulnerable

Axonal length: Longer axons experience more transport stress

Metabolic demand: High energy requirements increase ROS

Calcium homeostasis: Pacemaking increases calcium influx

Synaptic activity: High synaptic activity increases exposure

Protein expression: Higher α-syn expression increases aggregation risk

Lewy Body Subtypes

Cortical Lewy Bodies

• Found in cerebral cortex
• Less defined halo
• Associated with dementia
• Less specific to PD
• Higher density correlates with cognitive impairment

Brainstem Lewy Bodies

• Classic Lewy bodies
• Defined halo
• Nigral degeneration
• Motor symptoms correlate
• Higher density with disease severity

Intermediate Lewy Bodies

• Limbic system distribution
• Transitional forms
• Associated with PDD (Parkinson's disease with dementia)

Clinical Correlations

Motor Symptoms

• Nigral Lewy bodies → bradykinesia, rigidity
• Disease severity correlates with burden
• Tremor may not directly correlate with LB density

Non-Motor Symptoms

| Symptom | Anatomical Correlation |
|---------|----------------------|
| Anosmia | Olfactory bulb |
| Depression, RBD | Locus coeruleus |
| Cognitive impairment | Cortex, limbic system |
| Autonomic dysfunction | Dorsal motor nucleus |

Biomarker Correlations

• CSF α-synuclein: Decreased (sequestration in Lewy bodies)
• DaT-SPECT: Presynaptic dopamine loss
• MIBG cardiac scan: Sympathetic denervation
• Skin biopsy: Phosphorylated α-syn in dermal nerves
• Blood/CSF seeding assays: Detect pathological α-syn

Toxicity Mechanisms

Oligomer Toxicity

Soluble oligomers are considered more toxic than fibrils:

• Membrane pore formation: Disrupt ion gradients
• ER stress: Trigger unfolded protein response
• Mitochondrial dysfunction: Affect ETC, ROS production
• Synaptic dysfunction: Impair neurotransmitter release
• Calcium dysregulation: Activate harmful pathways

Loss of Normal Function

α-syn has normal physiological roles:

• Regulation of synaptic vesicle pools
• Neurotransmitter release modulation
• Filamin A interactions
• Antiferroptosis function

Loss of these functions contributes to pathology.

Ferroptosis Connection

Recent evidence links α-syn to ferroptosis[@calo2016]:

• α-syn affects iron metabolism
• Lipid peroxidation in Lewy body disease
• GPX4 system alterations
• Ferroptosis inhibitors show promise in models

Therapeutic Implications

Targeting Lewy Body Formation

1. α-Synuclein aggregation inhibitors

• Small molecule inhibitors (e.g., anle138b, Synucleozid)
• Oligomer modulators
• Structure-based drug design

2. Protein clearance enhancers

• Autophagy inducers (rapamycin analogs)
• Proteasome activators
• Chaperone enhancement

3. Post-translational modification modulators

• Kinase inhibitors (for phosphorylation at Ser129)
• Antioxidants (for oxidation)
• Protease activators (for truncation)

4. Immunotherapies

• Active immunization (vaccines)
• Passive immunization (antibodies)
• Both in clinical trials

Targeting Propagation

Antisense oligonucleotides against SNCA (WVE-004, others)

Antibody-based blockade of spread

Exosome inhibitors

Tunneling nanotube disruptors

Clinical Trials

| Approach | Agent | Stage | Target |
|----------|-------|-------|--------|
| Immunotherapy | Cinpanemab | Phase 2 | Aβ |
| Immunotherapy | Prasinezumab | Phase 2 | α-syn |
| ASO | WVE-004 | Phase 1 | SNCA mRNA |
| Aggregation inhibitor | Anle138b | Phase 1 | Oligomers |
| Kinase inhibitor | Masitinib | Phase 3 | Multiple |

Existing Treatments

| Approach | Drug/Method | Mechanism |
|----------|-------------|-----------|
| Dopamine replacement | Levodopa | Symptomatic |
| Deep brain stimulation | Surgery | Circuit modulation |
| Cholinesterase inhibitor | Rivastigmine | Cognitive (DLB) |

Research Directions

Strain-Specific Therapies

• Distinguishing between strains
• Personalized approaches based on strain
• Strain-specific biomarkers

Early Intervention

• Identifying prodromal patients
• Pre-symptomatic treatment
• At-risk populations

Biomarker Development

• CSF/blood α-synuclein seeding assays (RT-QuIC, PMCA)
• PET ligands for Lewy bodies
• Skin biopsy for peripheral detection
• Blood biomarkers for diagnosis and progression

Cross-Linking and Related Mechanisms

• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation): Pathway overview
• [Alpha-Synuclein Clearance](/mechanisms/alpha-synuclein-clearance): Clearance mechanisms
• [Alpha-Synuclein Propagation](/mechanisms/alpha-synuclein-propagation): Prion-like spread
• [Parkinson's Disease](/diseases/parkinsons-disease): Disease context
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies): DLB overview
• [Braak Staging](/mechanisms/braak-staging-parkinsons): Staging system
• [Autophagy-Lysosome Pathway](/mechanisms/autophagy-lysosome-pathway): Clearance
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pd): Related mechanism

Conclusion

Lewy body pathogenesis represents a central mechanism in Parkinson's disease and Dementia with Lewy Bodies. The understanding of α-synuclein misfolding, aggregation, propagation, and toxicity has advanced dramatically, revealing potential therapeutic targets at every stage of the pathogenic process. The identification of distinct α-syn strains and their relationship to clinical phenotypes offers hope for personalized therapeutic approaches. Continued research into early detection, strain-specific biomarkers, and disease-modifying therapies remains essential for improving outcomes in these devastating disorders.

References

[Spillantini MG, et al, α-Synuclein in Lewy bodies (1997)](https://pubmed.ncbi.nlm.nih.gov/9193390/)

[Braak H, et al, Staging of brain pathology in sporadic Parkinson disease (2003)](https://pubmed.ncbi.nlm.nih.gov/14561870/)

[Goedert M, et al, α-Synuclein and neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28438714/)

[Peelaerts W, et al, α-Synuclein strains (2015)](https://pubmed.ncbi.nlm.nih.gov/26083780/)

[Luk KC, et al, Pathological α-synuclein transmission (2012)](https://pubmed.ncbi.nlm.nih.gov/22962490/)

[Fujiwara H, et al, α-Synuclein is phosphorylated at Ser129 (2002)](https://pubmed.ncbi.nlm.nih.gov/11780009/)

[Anderson JP, et al, Phosphorylation of Ser129 regulates aggregation (2006)](https://pubmed.ncbi.nlm.nih.gov/16410247/)

[Masliah E, et al, Effects of α-synuclein in Lewy body disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10688836/)

[Wong YC, Krainc D, α-Synuclein toxicity in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34290379/)

[Baba M, et al, Aggregation of α-synuclein in Lewy bodies (1998)](https://pubmed.ncbi.nlm.nih.gov/9600347/)

[Spillantini MG, Goedert M, The α-synucleinopathies (2003)](https://pubmed.ncbi.nlm.nih.gov/15028784/)

[Kalia LV, et al, Synaptic dysfunction and α-synuclein pathology (2013)](https://pubmed.ncbi.nlm.nih.gov/23585839/)

[Calo L, et al, Ferroptosis in α-synucleinopathies (2016)](https://pubmed.ncbi.nlm.nih.gov/27062241/)

[Martinez J, et al, Molecular mechanisms of α-synuclein seeding (2018)](https://pubmed.ncbi.nlm.nih.gov/29860562/)

[Walker L, et al, Neuropathological criteria for DLB (2013)](https://pubmed.ncbi.nlm.nih.gov/23563752/)

[McEnaney JD, et al, Lewy body pathology in transplant patients (2020)](https://pubmed.ncbi.nlm.nih.gov/32383894/)

[Prince WS, et al, α-Synuclein oligomerization (2019)](https://pubmed.ncbi.nlm.nih.gov/31124075/)

[Dermentzaki G, et al, Defining the toxic oligomer (2019)](https://pubmed.ncbi.nlm.nih.gov/30660894/)

[Taschenberger G, et al, Aggregated α-synuclein uptake (2013)](https://pubmed.ncbi.nlm.nih.gov/23575867/)

[Vogensen AK, et al, Strain differences in α-synuclein fibrils (2014)](https://pubmed.ncbi.nlm.nih.gov/24398690/)

[Sanders DW, et al, Distinct α-synuclein strains (2014)](https://pubmed.ncbi.nlm.nih.gov/24761211/)

[Guo JL, et al, α-Synuclein prion-like properties (2023)](https://pubmed.ncbi.nlm.nih.gov/37414920/)

Pathway Diagram

The following diagram shows the key molecular relationships involving lewy-body-pathogenesis discovered through SciDEX knowledge graph analysis: